Home > Insider Trading > Filing (0001181431-14-032981)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157602	Vitae Pharmaceuticals Inc	VTAE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1005561	J Peter Barris	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1132326	P L 10 Associates Enterprise New	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1219855	James M Barrett	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1236049	P L 10 Partners Nea	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1237289	D Scott Sandell	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-09-29	260,340	$0.00	260,340	No	4	C	Direct
Common Stock	Acquisiton	2014-09-29	1,479,058	$0.00	1,739,398	No	4	C	Direct
Common Stock	Acquisiton	2014-09-29	58,692	$0.00	1,798,090	No	4	C	Direct
Common Stock	Acquisiton	2014-09-29	813,474	$8.00	2,611,564	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Preferred Stock	Disposition	2014-09-29	172,825	$0.00	260,340	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-09-29	1,479,058	$0.00	1,479,058	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-09-29	58,692	$0.00	58,692	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
The shares are directly held by New Enterprise Associates 10, Limited Partnership ("NEA 10") and indirectly held by NEA Partners 10, Limited Partnership ("NEA Partners 10"), the sole general partner of NEA 10, and the individual general partners of NEA Partners 10 (NEA Partners 10 and its individual general partners together, the "Indirect Reporting Persons"). The individual general partners of NEA Partners 10 are Peter J. Barris, M. James Barrett and Scott D. Sandell. Each Indirect Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which such Indirect Reporting Person has no pecuniary interest.
Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.